Holen Sie sich die Stockscreener-App
0.9245
0.49%
0.0045
Handel nachbörslich:
.92
-0.0045
-0.49%
Schlusskurs vom Vortag:
$0.92
Offen:
$0.95
24-Stunden-Volumen:
97,844
Relative Volume:
0.84
Marktkapitalisierung:
$38.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.37M
KGV:
-0.6429
EPS:
-1.438
Netto-Cashflow:
$-4.23M
1W Leistung:
-2.15%
1M Leistung:
-5.68%
6M Leistung:
-37.53%
1J Leistung:
-22.96%
1-Tages-Spanne:
$0.904
$0.95
1-Wochen-Bereich:
$0.8961
$0.99
52-Wochen-Spanne:
$0.8961
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Firmenname
Mira Pharmaceuticals Inc
Sektor
Telefon
813-369-5150
Adresse
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.9245 | 38.85M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo
MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan
MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan
MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et
What's going on with MIRA Pharma stock Tuesday? - MSN
MIRAMira Pharmaceuticals Inc Options - Finviz
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo
MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com
Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView
K6S Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Flat at Open - Baystreet.ca
MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com
Mira Pharmaceuticals reports preclinical data on pain drug candidate - Investing.com
MIRA Pharmaceuticals Advances Mira-55 for Chronic Pain Relief - GuruFocus
Mira Pharmaceuticals reports preclinical data on pain drug candidate By Investing.com - Investing.com Australia
MIRA Unveils Differentiated Preclinical Data for Mira-55 - TipRanks
MIRA’s Mira-55 eases anxiety in preclinical tests, unlike THC - Stock Titan
MIRA reports preclinical Mira-55 data showing distinct mechanism, anxiolytic activity vs THC - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) highlights differentiated Mira-55 preclinical profile vs. THC - Stock Titan
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy - ACCESS Newswire
MIRA Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mira Pharmaceuticals Inc (MIRA) Institutional Confidence - TradingKey
Mira Pharmaceuticals Inc (MIRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mira Pharmaceuticals Inc (MIRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):